Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04149275
Title Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma
Recruitment Withdrawn
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Alabama at Birmingham
Indications

carcinosarcoma

Therapies

Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.